Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvalent, Inc.

83.15
-2.5400-2.96%
Volume:122.16K
Turnover:10.42M
Market Cap:5.97B
PE:-18.87
High:86.49
Open:86.49
Low:83.15
Close:85.69
Loading ...

Nuvalent Inc. Files Initial Statement of Beneficial Ownership for Director Christy J. Oliger

Reuters
·
21 Jun

BRIEF-Nuvalent appoints Christy Oliger to board of directors

Reuters
·
19 Jun

Nuvalent Inc. Appoints Christy Oliger to Board of Directors Amid Strategic Shift Toward Commercialization

Reuters
·
19 Jun

Nuvalent Appoints Christy Oliger to Board of Directors

THOMSON REUTERS
·
19 Jun

Press Release: Nuvalent Appoints Christy Oliger to Board of Directors

Dow Jones
·
19 Jun

Barclays Keeps Their Buy Rating on Nuvalent (NUVL)

TIPRANKS
·
18 Jun

Nuvalent Inc. Announces Board Member Emily Conley's Resignation Effective at 2025 Annual Meeting

Reuters
·
11 Jun

Nuvalent, Inc. Reports Q1 2025 Financial Results

TIPRANKS
·
31 May

Nuvalent’s Strategic Progress and Financial Stability Drive Buy Rating

TIPRANKS
·
09 May

Nuvalent Q1 EPS $(1.18) Misses $(1.09) Estimate

Benzinga
·
08 May

Nuvalent Q1 EPS USD -1.18

THOMSON REUTERS
·
08 May

Press Release: Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Dow Jones
·
08 May

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

PR Newswire
·
30 Apr

Nuvalent Board Member Resigns, Joins Advisory Board

TIPRANKS
·
18 Apr

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Brainstorm Cell Therapeutics (BCLI)

TIPRANKS
·
10 Apr

Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now?

Insider Monkey
·
01 Apr

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

PR Newswire
·
01 Apr

Optimistic Outlook on Nuvalent’s Zidesaminib: Promising Phase 1 Results and Strategic Positioning in ROS1-Positive NSCLC Market

TIPRANKS
·
31 Mar

Nuvalent Raised to Buy From Neutral by UBS

Dow Jones
·
14 Mar

UBS Upgrades Nuvalent to Buy From Neutral, Maintains $100 Price Target

MT Newswires Live
·
14 Mar